Vascular Clinic Dr. Baraldi
Via Vincenzo Aloi, 1
Catanzaro
Expert in Vascular and Endovascular Surgery
Biography
Dr. Christian Baraldi is among the leading experts in the field of minimally invasive varicose vein surgery. After graduating in Medicine and Surgery from the University of Catanzaro, she specialized in Cardiac Surgery in 2002 at the University of Siena with 70/70 and honors. Following more than a year and a half training in Cardio-Thoraco-Vascular surgery carried out in Belgium (Catholic University of Leuven) and Spain (University of Pais Vasco), Dr. Baraldi specializes in arterial endovascular surgery by starting the treatment endoprosthetic of the thoraco-abdominal aorta at the S. Anna Hospital of Catanzaro in 2005. In 2006 Dr. Baraldi perfected himself in the endovascular treatment of the VARICOSE VEINS with LASER.
In 2007 he was the first to carry out thermo-ablation operations on the large and small saphenous veins with LASER in Calabria and Eastern Sicily. In 2009, after perfecting with Dr. Francesco Zini and Dr. Lorenzo Tessari, he began to perform the Scleromousse according to the Tessari method first. In 2010, he publishes at the International Congress of the ESCVS (European Society of Cardiovascular Surgery) a scientific work on the personalization of the endovascular method with laser according to the caliber of the target vein.
In 2019 Dr. Baraldi was elected National Councilor of one of the most prestigious Phlebological Societies, the "Italian Society of Phlebo-Lymphology".
Education & Training
1997
Degree in medicine and surgery University of Catanzaro
2002
Specialization in Cardiac Surgery
University of Siena with a score of 70/70 and praise
2000
Fellowship, Cardio-Vascular Surgery
Hospital de Mont Godine - Catholic University of Leuven, Belgium
2000-2001
Fellowship, Cardio-Thoraco-Vascular Surgery
Hospital de Cruces, Barakaldo (Bilbao) and Virgen Blanca, Bilbao - Spain
2005
Specialization in Aortic Endovascular Surgery
Hospital Cardiologique CHU of Lille, France
2021
Organizer and President
of the international LIVE VENOUS SYMPOSIUM
2023
Organizer and Trainer of Flebocorso Italia - Hands on Training Course
2024
Lecturer/Professor and Head of the Catanzaro Training Center. SIC-SICVE National Reference School of Phlebologic Surgery.
Publications
Vascular and Endovascular Surgery. 2024;58(1):60-64.
Safety and Efficacy of Combining Saphenous Endovenous Laser Ablation and Varicose Veins Foam Sclerotherapy: An Analysis on 5500 Procedures in Patients With Advance Chronic Venous Disease (C3-C6).
C. Baraldi, MD
Abstract
Background: endovenous laser ablation (EVLA) represents the gold standard in treating both great and small saphenous veins (GSV and SSV) incompetence. To achieve a “no-scalpel” procedure in patients with chronic venous insufficiency (CVI, CEAP C3-C6), concomitant phlebectomies could be replaced by ultrasound-guided foam sclerotherapy (UGFS) into varicose tributaries. The aim of this study is to present a single-centre experience on EVLA + UGFS for patients with CVI secondary to varicose veins and saphenous trunk incompetence, analysing ling-term outcomes.
Methods: all consecutive patients with CVI and treated by EVLA + UGFS from 2010 to 2022 were included in the analysis. EVLA was performed using a 1470-nm diode laser (LASEmaR® 1500, Eufoton, Trieste, Italy), adapting the linear endovenous energy density (LEED) depending on saphenous trunk diameter. Tessari method was used for UGFS. Patients were evaluated clinically and by duplex scanning at 1, 3 and 6 months, and annually up to 4 years, to assess treatment efficacy and adverse reactions.
Results: 5500 procedures in 4895 patients (3818 women, 1077 men) with a mean age of 51.4 years were analysed during the study period. A total of 3950 GSVs and 1550 SSVs were treated with EVLA + UGFS (C3 59%, C4 23%, C5 17% and C6 1%). Neither deep vein thrombosis nor pulmonary embolism were detected during follow-up, as well as superficial burns. Ecchymoses (7%), transitory paraesthesia (2%), palpable vein induration/superficial vein thrombosis (15%) and transient dyschromia (1%) were registered. Saphenous and tributaries closure rate at 30 days, 1 and 4 years were 99.1%, 98.3% and 97.9%, respectively. Conclusions: EVLA + UGFS for an extremely minimally invasive procedure appears to be a safe technique, with only minor effects and acceptable long-term outcomes, in patients with CVI. Further prospective randomized studies are needed to confirm the role of this combined therapy in such patients.
Acta Phlebologica 2024 August;25(2):81-4
Endovenous laser ablation in treating perforating veins: technical notes and 1-year outcomes.
C. Baraldi, MD
Abstract
Background: endovenous laser ablation (EVLA) represents the gold standard in treating both great and small saphenous veins (GSV and SSV) incompetence, despite few data have been reported on perforating veins (PVs). the aim of this study is to collect PVs treatment outcomes after eVlA, highlighting technical notes and decision making for the treatment.
Methods: From September 2012 to December 2022, all consecutive patients with PVs matching with inclusion criteria for endovenous ablation were selected and treated. A 1470-nm diode laser (LASEmaR 1500, Eufoton, Trieste, Italy), with a kit that including 400-600-micron frontal optical fibers (Eufoton, Italy) was used. The optimal linear intravenous energy density (LEED) for the treatment was set according to PV diameter measured in an upright position in transversal section. The fiber tip was placed 1 cm from the deep venous PV margin. PVs’ characteristics as well as concomitant endovenous procedures were collected. Patients were evaluated clinically and by duplex scan 7 days, 6 months, and at 1 year after the procedure, assessing PV
closure rate and adverse events.
Results:
During the study period, a total of 147 PVs were treated in 143 patients (86 men, 57 women with a mean age of 51 years [range, 34 to 86 years] with CEAP classes of C2 (N.=47), C3C4 (N.=69), C5-C6 (N.=27). EVLA was used to treat Hach (N.=26), Cockett (N.=29), Cockett (N.=31), Sherman (N.=12), Dodd (N.=49) perforating veins. The mean PV diameter was 6.5 mm (range, 4.0 to 6.5). The LEED was adjusted from 40 J/cm (4.0 mm) up to 60 J/cm (6.5 mm). concomitant procedures were GSV/SSV EVLA ablation (N.=49), tributaries foam sclerotherapy (N.=141), others (two phlebectomies). At 7-day follow-up period, the closure rate was 100% and remained constant 1-year after the treatment. In 87 (60.8%) cases, complete disappearance of the perforators veins or residual fibrous cord
was noted. No major complications were described; ecchymosis was seen in 17 (11.8%) patients.
Conclusions:
The EVLA of PVs with a 1470-nm diode laser and a frontal fiber seems to be an extrem ely safe technique, particularly when the applied leeD is calculated as a function of the PV diameter. Careful decision making is essential in choosing to treat PVs, balancing venous hemodynamic changes and clinical outcomes.